Melina J Windon1, Gypsyamber D'Souza1,2, Eleni M Rettig1, William H Westra3, Annemieke van Zante4, Steven J Wang4, William R Ryan4, Wojciech K Mydlarz1, Patrick K Ha4, Brett A Miles5, Wayne Koch1, Christine Gourin1, David W Eisele1, Carole Fakhry1,2,6. 1. Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland. 2. Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland. 3. Department of Pathology, Johns Hopkins University, Baltimore, Maryland. 4. Head and Neck Surgery, Department of Otolaryngology, University of California San Francisco, San Francisco, California. 5. Department of Otolaryngology Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York. 6. Johns Hopkins Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland.
Abstract
BACKGROUND: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) is increasing among older adults. It is unknown whether these trends can be explained by human papillomavirus (HPV) and whether HPV-related tumors remain associated with an improved prognosis among older patients. METHODS: In a retrospective study of OPSCCs diagnosed from 1995 to 2013 at 2 National Comprehensive Cancer Network-designated cancer centers, p16 immunohistochemistry and in situ hybridization (ISH) for HPV-16, high-risk DNA, and/or E6/E7 RNA were performed. The median age at diagnosis was compared by p16 and ISH tumor status. Trends in age were analyzed with nonparametric trends. Survival was analyzed with the Kaplan-Meier method and Cox proportional hazards models. RESULTS: Among 239 patients, 144 (60%) were p16-positive. During 1998-2013, the median age increased among p16-positive patients (Ptrend = .01) but not among p16-negative patients (Ptrend = .71). The median age of p16-positive patients increased from 53 years (interquartile range [IQR] in 1995-2000, 45-65 years) to 58 years (IQR for 2001-2013, 53-64 years). Among patients ≥ 65 years old, the proportion of OPSCCs that were p16-positive increased from 41% during 1995-2000 to 75% during 2007-2013 (Ptrend = .04). Among all age groups, including older patients, a p16-positive tumor status conferred improved overall survival in comparison with a p16-negative status. CONCLUSIONS: The median age at diagnosis for HPV-related OPSCC is increasing as the proportion of OPSCCs caused by HPV rises among older adults. The favorable survival conferred by an HPV-positive tumor status persists in older adults. Cancer 2018;124:2993-9.
BACKGROUND: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) is increasing among older adults. It is unknown whether these trends can be explained by human papillomavirus (HPV) and whether HPV-related tumors remain associated with an improved prognosis among older patients. METHODS: In a retrospective study of OPSCCs diagnosed from 1995 to 2013 at 2 National Comprehensive Cancer Network-designated cancer centers, p16 immunohistochemistry and in situ hybridization (ISH) for HPV-16, high-risk DNA, and/or E6/E7 RNA were performed. The median age at diagnosis was compared by p16 and ISH tumor status. Trends in age were analyzed with nonparametric trends. Survival was analyzed with the Kaplan-Meier method and Cox proportional hazards models. RESULTS: Among 239 patients, 144 (60%) were p16-positive. During 1998-2013, the median age increased among p16-positive patients (Ptrend = .01) but not among p16-negative patients (Ptrend = .71). The median age of p16-positive patients increased from 53 years (interquartile range [IQR] in 1995-2000, 45-65 years) to 58 years (IQR for 2001-2013, 53-64 years). Among patients ≥ 65 years old, the proportion of OPSCCs that were p16-positive increased from 41% during 1995-2000 to 75% during 2007-2013 (Ptrend = .04). Among all age groups, including older patients, a p16-positive tumor status conferred improved overall survival in comparison with a p16-negative status. CONCLUSIONS: The median age at diagnosis for HPV-related OPSCC is increasing as the proportion of OPSCCs caused by HPV rises among older adults. The favorable survival conferred by an HPV-positive tumor status persists in older adults. Cancer 2018;124:2993-9.
Authors: Stephanie A Michal; David J Adelstein; Lisa A Rybicki; Cristina P Rodriguez; Jerrold P Saxton; Benjamin G Wood; Joseph Scharpf; Denise I Ives Journal: Head Neck Date: 2011-10-22 Impact factor: 3.147
Authors: Carole Fakhry; Qiang Zhang; Phuc Felix Nguyen-Tan; David Rosenthal; Adel El-Naggar; Adam S Garden; Denis Soulieres; Andy Trotti; Vilija Avizonis; John Andrew Ridge; Jonathan Harris; Quynh-Thu Le; Maura Gillison Journal: J Clin Oncol Date: 2014-06-23 Impact factor: 44.544
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Gypsyamber D'Souza; Yuehan Zhang; Samantha Merritt; Dorothy Gold; Hilary A Robbins; Victoria Buckman; Jennifer Gerber; David W Eisele; Patrick Ha; Joseph Califano; Carole Fakhry Journal: Oral Oncol Date: 2016-07-17 Impact factor: 5.337
Authors: Francesca Caparrotti; Brian O'Sullivan; Scott V Bratman; Jolie Ringash; Lin Lu; Andrew Bayley; John Cho; Meredith Giuliani; Andrew Hope; John Kim; John Waldron; Aaron Hansen; David Goldstein; Bayardo Perez-Ordonez; Ilan Weinreb; Li Tong; Yuyao Song; Wei Xu; Shao Hui Huang Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-27 Impact factor: 7.038
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Lauren Ottenstein; Hannah Cornett; Jeffrey M Switchenko; Meghana Nathan; Susan Thomas; Amanda I Gillespie; Nancy McColloch; Tiffany Barrett; Matthew B Studer; Meghan Brinkman; Azeem S Kaka; Brian J Boyce; Robert L Ferris; Ashley H Aiken; Mark El-Deiry; Jonathan J Beitler; Mihir R Patel Journal: Head Neck Date: 2021-02-05 Impact factor: 3.147
Authors: Joseph E Tota; Ana F Best; Zachary S Zumsteg; Maura L Gillison; Philip S Rosenberg; Anil K Chaturvedi Journal: J Clin Oncol Date: 2019-04-26 Impact factor: 44.544
Authors: Laura Martin-Gomez; William J Fulp; Michael J Schell; Bradley Sirak; Martha Abrahamsen; Kimberly A Isaacs-Soriano; Attila Lorincz; Bruce Wenig; Christine H Chung; Jimmy J Caudell; Anna R Giuliano Journal: Oral Oncol Date: 2019-04-03 Impact factor: 5.337
Authors: Melina J Windon; Gypsyamber D'Souza; Farhoud Faraji; Tanya Troy; Wayne M Koch; Christine G Gourin; Ana P Kiess; Karen T Pitman; David W Eisele; Carole Fakhry Journal: Cancer Date: 2019-01-15 Impact factor: 6.860
Authors: Carole Fakhry; Tim Waterboer; William H Westra; Lisa M Rooper; Melina Windon; Tanya Troy; Wayne Koch; Christine G Gourin; Noemi Bender; Siddhartha Yavvari; Ana P Kiess; Brett A Miles; William R Ryan; Patrick K Ha; David W Eisele; Gypsyamber D'Souza Journal: Oral Oncol Date: 2019-12-24 Impact factor: 5.337